2021
DOI: 10.1186/s12886-020-01771-9
|View full text |Cite
|
Sign up to set email alerts
|

Genetic pre-screening for glaucoma in population-based epidemiology: protocol for a double-blind prospective screening study within Lifelines (EyeLife)

Abstract: Background Early detection of glaucoma is paramount to maintain patients’ eyesight, however glaucomatous vision loss tends to begin in the periphery with up to 50% of patients unaware they are affected. Because glaucomatous vision loss is permanent, screening appears attractive, but currently is not cost-effective. Therefore we aim to investigate the utility of genetic pre-screening for glaucoma in a population-based setting, called EyeLife. Methods … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1
1

Relationship

3
7

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 49 publications
0
6
0
Order By: Relevance
“…Following quality control, both genotyping datasets were then imputed into the Sanger imputation server using the Haplotype Reference Consortium panel r1.1 [ 24 ]. Details of genotyping, quality control, and imputation in Lifelines have been published elsewhere [ 25 ].…”
Section: Methodsmentioning
confidence: 99%
“…Following quality control, both genotyping datasets were then imputed into the Sanger imputation server using the Haplotype Reference Consortium panel r1.1 [ 24 ]. Details of genotyping, quality control, and imputation in Lifelines have been published elsewhere [ 25 ].…”
Section: Methodsmentioning
confidence: 99%
“…After quality control, both genotyping datasets were then imputed at the Sanger imputation server using the Haplotype Reference Consortium panel r1.1 36 . Details of genotyping, quality control, and imputation in Lifelines have been published elsewhere 37 . Two PRSs of ASD were calculated in the Lifelines samples based on the summary statistics of ASD GWAS and ASD MTAG results, respectively.…”
Section: Prs Analysesmentioning
confidence: 99%
“…GRS have not yet been established as a clinical screening tool for POAG. Neustaeter and colleagues are testing feasibility of POAG GRS for clinical screening using a prospective approach [38], but the variants included in the GRS were identified from POAG GWAS in European-descent individuals. In European-descent samples, a higher burden of genetic risk captured by PRS is associated with POAG age at diagnosis and disease-relevant clinical parameters [15,16].…”
Section: Clinical Applicability Of Genetic Data In Poag Risk Stratifi...mentioning
confidence: 99%